A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers

AIMS: The pharmacokinetic (PK) similarity between MB02, a proposed bevacizumab biosimilar, and reference bevacizumab approved from the USA (US‐bevacizumab) and European Union (EU‐bevacizumab) was evaluated. Safety and immunogenicity were also assessed. METHODS: In this phase 1, randomized, double bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinn, Angela, García‐Alvarado, Fernanda, Gonzalez, Veronica, Huerga, Camino, Bullo, Felicitas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291832/
https://www.ncbi.nlm.nih.gov/pubmed/34374114
http://dx.doi.org/10.1111/bcp.15032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291832/
https://www.ncbi.nlm.nih.gov/pubmed/34374114
http://dx.doi.org/10.1111/bcp.15032

Ejemplares similares